MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Perrigo Company plc Total Assets 2011-2026 | PRGO
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Perrigo Company plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.54 B | 9.65 B | 10.8 B | 11 B | 10.4 B | 11.5 B | 11.3 B | 11 B | 11.6 B | 13.9 B | 19.7 B | 13.9 B | 5.35 B | 4.02 B | 3.19 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.7 B | 3.19 B | 10.4 B |
Quarterly Total Assets Perrigo Company plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.1 B | 10.1 B | 9.76 B | 9.65 B | 11.2 B | 10.4 B | 10.6 B | 10.8 B | 10.8 B | 11 B | 11 B | 11 B | 10.7 B | 10.9 B | 10.4 B | 10.4 B | 10.9 B | 11.2 B | 11.3 B | 11.5 B | 11.5 B | 11.5 B | 11.5 B | 11.3 B | 11.3 B | 11.3 B | 11.3 B | 11 B | 11 B | 11 B | 11 B | 11.6 B | 11.6 B | 11.6 B | 11.6 B | 13.9 B | 13.9 B | 13.9 B | 13.9 B | 19.3 B | 19.3 B | 19.3 B | 19.3 B | 16.5 B | 13.8 B | 13.9 B | 13.8 B | 13.7 B | 5.51 B | 13.7 B | 13.1 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 19.3 B | 13.1 M | 11.9 B |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
29.7 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
10.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
164 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
7.07 M | - | - | $ 36.6 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
75.6 M | $ 3.05 | -2.24 % | $ 42.9 M | USA |
 |
Cronos Group
CRON
|
1.93 B | $ 2.58 | 0.19 % | $ 1.33 B |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Sundial Growers
SNDL
|
1.34 B | $ 1.41 | 2.55 % | $ 3.37 M | Canada |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 5.71 | -0.26 % | $ 2.08 B | Canada |
 |
Tilray
TLRY
|
4.31 B | $ 6.89 | 2.53 % | $ 4.26 B | Canada |
 |
Harrow Health
HROW
|
399 M | $ 37.97 | 2.35 % | $ 1.4 B | USA |
 |
Aurora Cannabis
ACB
|
853 M | $ 3.53 | 1.44 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
918 M | $ 1.09 | 0.46 % | $ 117 M | Canada |
 |
Veru
VERU
|
60.4 M | $ 2.39 | 0.42 % | $ 322 M | USA |
 |
Jupiter Wellness
JUPW
|
41 M | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
408 M | $ 1.43 | 1.04 % | $ 402 M | Canada |
 |
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | USA |
 |
Viatris
VTRS
|
50 B | $ 13.97 | 0.98 % | $ 16.8 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
289 M | - | - | $ 193 M | Canada |
 |
Evolus
EOLS
|
226 M | $ 4.39 | 1.5 % | $ 283 M | USA |
 |
Emergent BioSolutions
EBS
|
1.82 B | $ 8.53 | 3.52 % | $ 437 M | USA |
 |
Organogenesis Holdings
ORGO
|
498 M | $ 2.47 | 3.57 % | $ 325 M | USA |
 |
Pacira BioSciences
PCRX
|
1.55 B | $ 23.72 | -1.41 % | $ 1.1 B | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
ProPhase Labs
PRPH
|
87.6 M | - | - | $ 5.07 M | USA |
 |
Relmada Therapeutics
RLMD
|
94 M | $ 7.24 | -1.9 % | $ 286 M | USA |
 |
Assertio Holdings
ASRT
|
267 M | $ 18.02 | 0.03 % | $ 115 M | USA |
 |
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
10.6 M | $ 0.73 | -2.42 % | $ 3.15 M | USA |
 |
OptiNose
OPTN
|
108 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
59 M | $ 1.03 | 1.98 % | $ 51.4 M | USA |
 |
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
233 M | $ 8.24 | -1.73 % | $ 721 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
13.7 M | $ 2.17 | -7.66 % | $ 2.69 M | USA |
 |
Zomedica Corp.
ZOM
|
127 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
55.5 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
57.1 M | $ 0.91 | -2.76 % | $ 32.7 M | USA |
 |
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
31 M | $ 0.63 | -3.05 % | $ 2.7 M |  China |
 |
TherapeuticsMD
TXMD
|
37.7 M | $ 2.15 | 4.63 % | $ 24.9 M | USA |